GLP-1 பக்க விளைவுகள் & பாதுகாப்பு: இந்திய நோயாளிகள் தெரிந்து கொள்ள வேண்டியவை

GLP-1 most common side effect?

GI symptom GLP-1 RA most frequent early treatment 20–40%. Nausea most, vomiting, diarrhoea, constipation, bloating, reflux follow. Drug class work directly relate: gastric emptying slow, appetite signal reduce. Indian clinical practice large traditional thali, heavy fried, late dinner first month symptom more notice. Dose titration—low start 4–8 week gradually increase—specifically minimise. Week 8 body adapt significant improve report most. Smaller portion, greasy avoid, comfortably full (stuffed not) eat considerably help. Vomiting dehydration kidney function marker worsen—Indian summer heat, GLP-1 fluid loss combine fluid intake matter.

Dose titration

Weeks medicine dose gradually increase—tolerance improve, nausea side effect reduce.

Dose titration nausea manage how?

Indian patient successful practical: injection light meal after (oral semaglutide empty stomach require unless). Ginger tea, smaller frequent meal, eat immediately after lie down avoid help. Severe nausea doctor titration slow—full dose rush no benefit. Short-term anti-nausea medicine occasionally prescribe. Each dose increase first 4 week fatty festival, heavy restaurant meal avoid. Women cyclical tolerance variation notice. Nausea adequate nutrition prevent/intended beyond weight loss care team contact. Slow titration persistent symptom another GLP-1 RA switch/meal timing Indian diet familiar dietitian adjust. RSSDI initiation patient education—normal know unnecessary discontinuation reduce.

Common vs serious GLP-1 side effect

• Symptom: Mild nausea after meals — Likely severity: Common; often transient — Action: Smaller meals; continue if tolerable
• Symptom: Occasional constipation — Likely severity: Common — Action: Fibre, fluids; discuss if persistent
• Symptom: Severe abdominal pain to back — Likely severity: Rare; serious — Action: Urgent care; possible pancreatitis
• Symptom: Persistent vomiting >24 hours — Likely severity: Serious — Action: Medical review; hydration risk
• Symptom: Neck lump, hoarseness — Likely severity: Rare; serious — Action: Urgent endocrine evaluation
• Symptom: Allergic swelling, breathlessness — Likely severity: Rare; emergency — Action: Emergency services immediately

Serious risk know what?

Pancreatitis (pancreas inflammation) GLP-1 RA CDSCO, global agency post-marketing surveillance report. Severe persistent abdominal pain back radiate, vomiting with/without. Gallbladder disease—gallstone, cholecystitis—rapid weight loss partly relate. Allergic reaction, injection-site reaction weekly pen uncommon. Prolonged vomiting dehydration acute kidney injury secondary. GLP-1 RA alone hypoglycaemia rare; sulfonylurea/insulin combine risk rise—RSSDI companion medicine dose adjust recommend. Blood sugar very rapid drop diabetic retinopathy transient worsen some—existing retinopathy ophthalmology follow-up important. CDSCO Schedule H physician supervision why casual self-medication not.

GLP-1 therapy thyroid precaution?

Rodent study very high GLP-1 RA exposure medullary thyroid carcinoma (MTC). Human risk uncertain; regulatory precaution: MTC/MEN2 personal/family history GLP-1 RA contraindicated. Therapy start before doctor MTC first-degree relative, neck lump, hoarseness, swallowing difficulty ask. GLP-1 initiation solely routine thyroid ultrasound screening universally not recommend; existing nodule evaluate. Indian endocrinology CDSCO-approved international safety label align. Family thyroid cancer history physician withhold not—prescribing directly affect. Social media GLP-1 "everyone thyroid cancer cause" current human evidence not support; MTC/MEN2 history contraindication firm.

Severe abdominal pain, fluid intake prevent persistent vomiting, allergic reaction sign (swelling, breathing difficulty), pancreatitis suggest symptom emergency care seek.

GLP-1 RA use not who?

Contraindication, caution: pregnancy, breastfeeding; MTC/MEN2 personal/family history; severe pancreatitis history; type 1 diabetes (not indicated); diabetic ketoacidosis; drug class hypersensitivity. Severe gastroparesis, IBD flare, severe renal impairment caution. Frail elderly low BMI individualised risk-benefit—healthy limit beyond weight loss concern. Inadequately treated eating disorder psychiatric support before appetite-suppress medicine. Ayurvedic/herbal glucose-lowering supplement other diabetes drug hypoglycaemia risk compound— all supplement doctor disclose. ICMR obesity guidance contraindication exist pharmacotherapy not appropriate BMI/social pressure regardless.